Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C

Journal of Medicinal Chemistry

Volumn 52, Issue 13, 2009, Pages 3969-3981

  Af Gennäs, Gustav Boije ^a   Talman, Virpi ^a   Aitio, Olli ^b   Ekokoski, Elina ^a   Finel, Moshe ^a   Tuominen, Raimo K ^a   Yli Kauhaluoma, Jari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIS(1 ETHYLBUTYL) 5 (HYDROXYMETHYL)ISOPHTHALATE; BIS(1 ETHYLPENTYL) 5 (HYDROXYMETHYL)ISOPHTHALATE; BIS(3 TRIFLUOROMETHYLBENZYL) 5 (HYDROXYMETHYL)ISOPHTHALATE; BRYOSTATIN 1; DIOCTANOIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHORBOL ESTER; PHTHALIC ACID DERIVATIVE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; DRUG DESIGN; ENZYME ACTIVATION; HELA CELLS; HUMANS; INSECTS; PHOSPHORYLATION; PHTHALIC ACIDS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649921434     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900229p     Document Type: Article

References (57)

1. Battaini, F.; Mochly-Rosen, D. Happy birthday protein kinase C: past, present and future of a superfamily. Pharmacol. Res. 2007, 55, 461-466.
2. Koivunen, J.; Aaltonen, V.; Peltonen, J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006, 235, 1-10.
3. Griner, E. M.; Kazanietz, M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer. 2007, 7, 281-294.
4. Das Evcimen, N.; King, G. L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 2007, 55, 498-510.
5. Bright, R.; Mochly-Rosen, D. The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke 2005, 36, 2781-2790.
6. Chou, W. H.; Messing, R. O. Protein kinase C isozymes in stroke. Trends Cardiovasc. Med. 2005, 15, 47-51.
7. Sabri, A.; Steinberg, S. F. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol. Cell. Biochem. 2003, 251, 97-101.
8. Alkon, D. L.; Sun, M. K.; Nelson, T. J. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol. Sci. 2007, 28, 51-60.
9. Hofmann, J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr. Cancer. Drug Targets 2004, 4, 125-146.
10. Newton, A. C. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 2001, 101, 2353-2364.
11. Steinberg, S. F. Structural basis of protein kinase C isoform function. Physiol. Rev. 2008, 88, 1341-1378.
12. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258, 607-614.
13. Kazanietz, M. G. Novel "nonkinase" phorbol ester receptors: the C1 domain connection. Mol. Pharmacol. 2002, 61, 759-767.
14. Colon-Gonzalez, F.; Kazanietz, M. G. C1 domains exposed: from diacylglycerol binding to protein-protein interactions. Biochim. Biophys. Acta 2006, 1761, 827-837.
15. Yang, C.; Kazanietz, M. G. Divergence and complexities in DAG signaling: looking beyond PKC. Trends Pharmacol. Sci. 2003, 24, 602-608.
16. Parker, P. J.; Coussens, L.; Totty, N.; Rhee, L.; Young, S.; Chen, E.; Stabel, S.; Waterfield, M. D.; Ullrich, A. The complete primary structure of protein kinase C - the major phorbol ester receptor. Science 1986, 233, 853-859.
17. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
18. Blumberg, P. M.; Kedei, N.; Lewin, N. E.; Yang, D.; Czifra, G.; Pu, Y.; Peach, M. L.; Marquez, V. E. Wealth of opportunity - the C1 domain as a target for drug development. Curr. Drug Targets 2008, 9, 641-652.
19. Cameron, A. J.; Procyk, K. J.; Leitges, M.; Parker, P. J. PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival. Int. J. Cancer 2008, 123, 769-779.
20. Zeidman, R.; Lofgren, B.; Pahlman, S.; Larsson, C. PKCepsilon, via its regulatory domain and independently of its catalytic domain, induces neurite-like processes in neuroblastoma cells. J. Cell Biol. 1999, 145, 713-726.
21. Ono, Y.; Fujii, T.; Igarashi, K.; Kuno, T.; Tanaka, C.; Kikkawa, U.; Nishizuka, Y. Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 4868-4871.
22. Smith, J. B.; Smith, L.; Pettit, G. R. Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem. Biophys. Res. Commun. 1985, 132, 939-945.
23. Kozikowski, A. P.; Wang, S.; Ma, D.; Yao, J.; Ahmad, S.; Glazer, R. I.; Bogi, K.; Acs, P.; Modarres, S.; Lewin, N. E.; Blumberg, P. M. Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity. J. Med. Chem. 1997, 40, 1316-1326.
24. Kong, F. H.; Kishi, Y.; Perez-Sala, D.; Rando, R. R. The pharmacophore of debromoaplysiatoxin responsible for protein kinase C activation. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1973-1976.
25. Kedei, N.; Lundberg, D. J.; Toth, A.; Welburn, P.; Garfield, S. H.; Blumberg, P. M. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004, 64, 3243-3255.
26. Shao, L.; Lewin, N. E.; Lorenzo, P. S.; Hu, Z.; Enyedy, I. J.; Garfield, S. H.; Stone, J. C.; Marner, F. J.; Blumberg, P. M.; Wang, S. Iridals are a novel class of ligands for phorbol ester receptors with modest selectivity for the RasGRP receptor subfamily. J. Med. Chem. 2001, 44, 3872-3880.
27. Marquez, V. E.; Blumberg, P. M. Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C). Acc. Chem. Res. 2003, 36, 434-443.
28. Duan, D.; Sigano, D. M.; Kelley, J. A.; Lai, C. C.; Lewin, N. E.; Kedei, N.; Peach, M. L.; Lee, J.; Abeyweera, T. P.; Rotenberg, S. A.; Kim, H.; Kim, Y. H.; Kazzouli, S. E.; Chung, J. U.; Young, H. A.; Young, M. R.; Baker, A.; Colburn, N. H.; Haimovitz-Friedman, A.; Truman, J. P.; Parrish, D. A.; Deschamps, J. R.; Perry, N. A.; Surawski, R. J.; Blumberg, P. M.; Marquez, V. E. Conformationally Constrained Analogues of Diacylglycerol. 29. Cells Sort Diacylglycerol-Lactone Chemical Zip Codes to Produce Diverse and Selective Biological Activities. J. Med. Chem. 2008, 51, 5198-5220.
29. Irie, K.; Nakagawa, Y.; Ohigashi, H. Toward the development of new medicinal leads with selectivity for protein kinase C isozymes. Chem. Rec. 2005, 5, 185-195.
30. Yanagita, R. C.; Nakagawa, Y.; Yamanaka, N.; Kashiwagi, K.; Saito, N.; Irie, K. Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes. J. Med. Chem. 2008, 51, 46-56.
31. Zhang, G.; Kazanietz, M. G.; Blumberg, P. M.; Hurley, J. H. Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Cell 1995, 81, 917-924.
32. Krauter, G.; Von der Lieth, C. W.; Schmidt, R.; Hecker, E. Structure/activity relationships of polyfunctional diterpenes of the tigliane type. A pharmacophore model for protein-kinase-C activators based on structure/activity studies and molecular modeling of the tumor promoters 12-O-tetradecanoylphorbol 13-acetate and 3-O-tetradecanoylingenol. Eur. J. Biochem. 1996, 242, 417-427.
33. Sugita, K.; Neville, C. F.; Sodeoka, M.; Sasai, H.; Shibasaki, M. Stereocontrolled syntheses of phorbol analogs and evaluation of their binding affinity to PKC. Tetrahedron Lett. 1995, 36, 1067-1070.
34. Benzaria, S.; Bienfait, B.; Nacro, K.; Wang, S.; Lewin, N. E.; Beheshti, M.; Blumberg, P. M.; Marquez, V. E. Conformationally constrained analogues of diacylglycerol (DAG). 15. The indispensable role of the sn-1 and sn-2 carbonyls in the binding of DAG-lactones to protein kinase C (PK-C). Bioorg. Med. Chem. Lett. 1998, 8, 3403-3408.
35. Wang, S.; Zaharevitz, D. W.; Sharma, R.; Marquez, V. E.; Lewin, N. E.; Du, L.; Blumberg, P. M.; Milne, G. W. The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database pharmacophore search. Molecular modeling studies. J. Med. Chem. 1994, 37, 4479-4489.
36. Kang, J. H.; Peach, M. L.; Pu, Y.; Lewin, N. E.; Nicklaus, M. C.; Blumberg, P. M.; Marquez, V. E. Conformationally constrained analogues of diacylglycerol (DAG). 25. Exploration of the sn-1 and sn-2 carbonyl functionality reveals the essential role of the sn-1 carbonyl at the lipid interface in the binding of DAG-lactones to protein kinase C. J. Med. Chem. 2005, 48, 5738-5748.
37. Nacro, K.; Bienfait, B.; Lee, J.; Han, K. C.; Kang, J. H.; Benzaria, S.; Lewin, N. E.; Bhattacharyya, D. K.; Blumberg, P. M.; Marquez, V. E. Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? J. Med. Chem. 2000, 43, 921-944.
38. Chen, M. H.; Davidson, J. G.; Freisler, J. T.; Iakovleva, E.; Magano, J. An Efficient and Scalable Synthesis of Methyl 3-Hydroxymethylbenzoate. Org. Prep. Proced. Int. 2000, 32, 381-384.
39. Parlow, J. J.; Case, B. L.; Dice, T. A.; Fenton, R. L.; Hayes, M. J.; Jones, D. E.; Neumann, W. L.; Wood, R. S.; Lachance, R. M.; Girard, T. J.; Nicholson, N. S.; Clare, M.; Stegeman, R. A.; Stevens, A. M.; Stallings, W. C.; Kurumbail, R. G.; South, M. S. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. J. Med. Chem. 2003, 46, 4050-4062.
40. Gopalakrishna, R.; Chen, Z. H.; Gundimeda, U.; Wilson, J. C.; Anderson, W. B. Rapid filtration assays for protein kinase C activity and phorbol ester binding using multiwell plates with fitted filtration discs. Anal. Biochem. 1992, 206, 24-35.
41. Ananthanarayanan, B.; Stahelin, R. V.; Digman, M. A.; Cho, W. Activation mechanisms of conventional protein kinase C isoforms are determined by the ligand affinity and conformational flexibility of their C1 domains. J. Biol. Chem. 2003, 278, 46886-46894.
42. Wender, P. A.; DeBrabander, J.; Harran, P. G.; Jimenez, J. M.; Koehler, M. F.; Lippa, B.; Park, C. M.; Siedenbiedel, C.; Pettit, G. R. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6624-6629.
43. Chang, L.; Karin, M. Mammalian MAP kinase signalling cascades. Nature 2001, 410, 37-40.
44. Schonwasser, D. C.; Marais, R. M.; Marshall, C. J.; Parker, P. J. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol. 1998, 18, 790-798.
45. Wang, Q. J.; Fang, T. W.; Fenick, D.; Garfield, S.; Bienfait, B.; Marquez, V. E.; Blumberg, P. M. The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein. J. Biol. Chem. 2000, 275, 12136-12146.
46. Wender, P. A.; Koehler, K. F.; Sharkey, N. A.; Dell'Aquila, M. L.; Blumberg, P. M. Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogs. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4214-4218.
47. 3H]Phorbol 12,13-dibutyrate binding assay for protein kinase C and related proteins. Methods Mol. Biol. 2003, 233, 129-156.
48. Giorgione, J. R.; Lin, J. H.; McCammon, J. A.; Newton, A. C. Increased membrane affinity of the C1 domain of protein kinase Cdelta compensates for the lack of involvement of its C2 domain in membrane recruitment. J. Biol. Chem. 2006, 281, 1660-1669.
49. Dries, D. R.; Gallegos, L. L.; Newton, A. C. A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J. Biol. Chem. 2007, 282, 826-830.
50. Hess, A. D.; Silanskis, M. K.; Esa, A. H.; Pettit, G. R.; May, W. S. Activation of human T lymphocytes by bryostatin. J. Immunol. 1988, 141, 3263-3269.
51. Pu, Y.; Perry, N. A.; Yang, D.; Lewin, N. E.; Kedei, N.; Braun, D. C.; Choi, S. H.; Blumberg, P. M.; Garfield, S. H.; Stone, J. C.; Duan, D.; Marquez, V. E. A novel diacylglycerol-lactone shows marked selectivity in vitro among C1 domains of protein kinase C (PKC) isoforms alpha and delta as well as selectivity for RasGRP compared with PKCalpha. J. Biol. Chem. 2005, 280, 27329-27338.
52. Galkin, A.; Pakkanen, J.; Vuorela, P. Development of an automated 7-day 96-well Caco-2 cell culture model. Pharmazie 2008, 63, 464-469.
53. Dewar, M. J. S.; Zoelbisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development and use of quantum mechanical molecular models. 76. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
54. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
55. Tammela, P.; Ekokoski, E.; García-Horsman, A.; Talman, V.; Finel, M.; Tuominen, R. K.; Vuorela, P. Screening of Natural Compounds and Their Derivatives as Potential Protein Kinase C Inhibitors. Drug Dev. Res. 2004, 63, 76-87.
56. Sandler, C.; Ekokoski, E.; Lindstedt, K. A.; Vainio, P. J.; Finel, M.; Sorsa, T.; Kovanen, P. T.; Golub, L. M.; Eklund, K. K. Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C. Inflamm. Res. 2005, 54, 304-312.
57. Kruger, N. J. The Bradford method for protein quantitation. Methods Mol. Biol. 1994, 32, 9-15.